Intangible Assets

Keros Therapeutics has no evident durable brand or proprietary commercial franchise versus larger biotech peers, so any pricing power is not structurally protected.

Its value is tied to a small number of clinical assets rather than a broad portfolio of protected intangibles, which makes peer substitution and pipeline risk high.

The provided profitability metrics are deeply negative, which indicates the company has not converted scientific assets into durable economic returns versus peers.

Compared with established biopharma peers that benefit from marketed-product brands and physician familiarity, Keros lacks a comparable intangible moat in commercialization.

Switching Costs

Keros does not appear to have meaningful customer switching costs because its business is development-stage and does not rely on recurring customer contracts or installed-base lock-in.

Physicians, payers, and distributors can shift to alternative therapies once approved, so retention is driven by clinical data rather than embedded switching frictions.

Compared with commercial-stage peers with formularies, reimbursement pathways, and treatment protocols, Keros has far weaker lock-in at this stage.

The absence of a large marketed product base means there is little structural retention benefit to support margins over a 5–10 year horizon.

Network Effects

Keros does not exhibit network effects because adoption of its pipeline assets does not become more valuable as more users join the platform.

Clinical development success depends on trial outcomes and regulatory approval, not on a self-reinforcing user ecosystem.

Compared with platform-like healthcare businesses or data-rich diagnostics peers, Keros has no visible flywheel that compounds competitive advantage.

Any scientific reputation benefit is indirect and too weak to qualify as a durable network effect versus peers.

Cost Advantage

The company shows no evidence of a structural cost advantage because negative ROIC and ROCE indicate capital is not being deployed more efficiently than peers.

As a small biotech, Keros likely faces fixed R&D and clinical-trial costs that are not inherently lower than larger peers with greater scale and vendor leverage.

Its asset turnover is very low, which suggests the asset base is not generating superior operating efficiency versus peers.

Compared with larger biopharma companies that can spread development, manufacturing, and regulatory overhead across more programs, Keros lacks a durable unit-cost edge.

Efficient Scale

Keros may benefit from some niche focus in a specialized therapeutic area, but the market is not large enough or protected enough to create strong efficient-scale economics.

The company is not yet operating at a scale where its presence alone deters competition or supports industry-wide rationalization versus peers.

Compared with large-cap biopharma peers, Keros has far less scale in R&D, manufacturing, and commercialization, which weakens any efficient-scale advantage.

Because the business is still dependent on pipeline execution, scale has not translated into a durable barrier to entry or sustained pricing power.

Overall Score

Keros Therapeutics has a weak economic moat versus peers because it lacks durable switching costs, network effects, and meaningful cost or scale advantages, while its intangible assets are still pipeline-dependent rather than commercially entrenched.